Current practice in proton therapy delivery in adult cancer patients across Europe

被引：38

作者：

Tambas, Makbule ^{[1
]}

Paul van der Laan, Hans ^{[1
]}

Steenbakkers, Roel J. H. M. ^{[1
]}

Doyen, Jerome ^{[2
]}

Timmermann, Beate ^{[3
,4
]}

Orlandi, Ester ^{[5
]}

Hoyer, Morten ^{[6
]}

Haustermans, Karin ^{[7
]}

Georg, Petra ^{[8
]}

Burnet, Neil G. ^{[9
]}

Gregoire, Vincent ^{[10
]}

Calugaru, Valentin ^{[11
,12
]}

Troost, Esther G. C. ^{[13
,14
,15
,16
,17
,18
,19
,20
,21
,22
,23
]}

Hoebers, Frank ^{[24
]}

Calvo, Felipe A. ^{[25
]}

Widder, Joachim ^{[26
]}

Eberle, Fabian ^{[27
]}

van Vulpen, Marco ^{[28
]}

Maingon, Philippe ^{[29
]}

Skora, Tomasz ^{[30
]}

Weber, Damien C. ^{[31
]}

Bergfeldt, Kjell ^{[32
]}

Kubes, Jiri ^{[33
,34
]}

Langendijk, Johannes A. ^{[1
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Radiat Oncol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands

[2] Univ Cote dAzur, Ctr Antoine Lacassagne, Dept Radiat Oncol, Nice, France

[3] Univ Hosp Essen, West German Proton Therapy Ctr Essen WPE, West German Canc Ctr WTZ, Dept Particle Therapy, Essen, Germany

[4] German Canc Consortium DKTK, Heidelberg, Germany

[5] Natl Ctr Oncol Hadrontherapy CNAO, Radiat Oncol Clin Dept, Pavia, Italy

[6] Aarhus Univ Hosp, Danish Ctr Particle Therapy, Aarhus, Denmark

[7] UZ Leuven, Dept Radiat Oncol, Leuven, Belgium

[8] MedAustron Ion Therapy Ctr, Wiener Neustadt, Austria

[9] Christie NHS Fdn Trust, Proton Beam Therapy Ctr, Manchester, Lancs, England

[10] Ctr Leon Berard, Radiat Oncol Dept, Lyon, France

[11] Inst Curie, Radiat Oncol Dept, Paris, France

[12] Proton Ctr, Orsay, France

[13] Tech Univ Dresden, OncoRay Natl Ctr Radiat Res Oncol, Fac Med, Helmholtz Zentrum Dresden Rossendorf, Dresden, Germany

[14] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Helmholtz Zentrum Dresden Rossendorf, Dresden, Germany

[15] Tech Univ Dresden, Dept Radiotherapy & Radiat Oncol, Fac Med, Dresden, Germany

[16] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany

[17] Helmholtz Zentrum Dresden Rossendorf, Inst Radiooncol OncoRay, Dresden, Germany

[18] Natl Ctr Tumor Dis NCT, Partner Site Dresden, Dresden, Germany

[19] German Canc Res Ctr, Heidelberg, Germany

[20] Tech Univ Dresden, Fac Med, Dresden, Germany

[21] Helmholtz Zentrum Dresden Rossendorf HZDR, Helmholtz Assoc, Dresden, Germany

[22] German Canc Consortium DKTK, Partner Site Dresden, Dresden, Germany

[23] German Canc Res Ctr, Partner Site Dresden, Dresden, Germany

[24] Maastricht Univ Med Ctr, GROW Sch Oncol & Dev Biol, MAASTRO Clin, Dept Radiat Oncol, Maastricht, Netherlands

[25] Univ Navarra, Dept Radiat Oncol, Madrid, Spain

[26] Med Univ Vienna, Comprehens Canc Ctr Vienna, Dept Radiat Oncol, Vienna, Austria

[27] Univ Hosp Marburg, Dept Radiotherapy & Radiooncol, Marburg Ion Beam Therapy Ctr MIT, Univ Ctr Tumor Dis Frankfurt & Marburg UCT, Marburg, Germany

[28] HollandPTC, Delft, Netherlands

[29] Sorbonne Univ, Hop Univ La Pitie Salpetriere, AP HP, Paris, France

[30] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Radiotherapy, Krakow, Poland

[31] ETH Domain, Paul Scheirer Inst, Ctr Proton Therapy, Zurich, Switzerland

[32] Skandion Clin, Uppsala, Sweden

[33] Motol Univ Hosp, Dept Oncol, Prague, Czech Republic

[34] Proton Therapy Ctr Czech, Prague, Czech Republic

来源：

RADIOTHERAPY AND ONCOLOGY | 2022年 / 167卷

关键词：

Proton therapy; Adult patients; Patient selection; Model-based approach; Reimbursement; Clinical studies; Europe; BEAM THERAPY; NECK-CANCER; MODEL; RADIOTHERAPY; SELECTION; HEAD;

D O I：

10.1016/j.radonc.2021.12.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background and purpose: Major differences exist among proton therapy (PT) centres regarding PT delivery in adult cancer patient. To obtain insight into current practice in Europe, we performed a survey among European PT centres. Materials and methods: We designed electronic questionnaires for eight tumour sites, focusing on four main topics: 1) indications and patient selection methods; 2) reimbursement; 3) on-going or planned studies, 4) annual number of patients treated with PT. Results: Of 22 centres, 19 (86%) responded. In total, 4233 adult patients are currently treated across Europe annually, of which 46% consists of patients with central nervous system tumours (CNS), 15% head and neck cancer (HNC), 15% prostate, 9% breast, 5% lung, 5% gastrointestinal, 4% lymphoma, 0.3% gynaecological cancers. CNS are treated in all participating centres (n = 19) using PT, HNC in 16 centres, lymphoma in 10 centres, gastrointestinal in 10 centres, breast in 7 centres, prostate in 6 centres, lung in 6 centres, and gynaecological cancers in 3 centres. Reimbursement is provided by national health care systems for the majority of commonly treated tumour sites. Approximately 74% of centres enrol patients for prospective data registration programs. Phase II-III trials are less frequent, due to reimbursement and funding problems. Reasons for not treating certain tumour types with PT are lack of evidence (30%), reimbursement issues (29%) and/or technical limitations (20%). Conclusion: Across European PT centres, CNS tumours and HNC are the most frequently treated tumour types. Most centres use indication protocols. Lack of evidence for PT and reimbursement issues are the most reported reasons for not treating specific tumour types with PT. (C) 2021 The Author(s). Published by Elsevier B.V.

引用

页码：7 / 13

页数：7

共 36 条

[11] Particle therapy of moving targets-the strategies for tumour motion monitoring and moving targets irradiation [J].